Last reviewed · How we verify

Liver transplant rejection — Treatment Landscape & Competitive Intelligence

Liver transplant rejection (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Liver transplant rejection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Prograf TACROLIMUS Astellas Pharma Calcineurin Inhibitor Immunosuppressant Interferon gamma 1994-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Astellas Pharma · 1 drug in Liver transplant rejection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Liver transplant rejection:

Cite this brief

Drug Landscape (2026). Liver transplant rejection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/liver-transplant-rejection. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing